CRS HIPEC may be considered for selected patients with peritoneal disease when careful assessment shows that surgery could form part of an appropriate treatment plan.
Peritoneal cancer can behave differently from cancers confined to a single organ. When tumour deposits develop across the abdominal lining, treatment planning may require assessment of disease distribution, involvement of nearby organs, overall health and whether complete or meaningful tumour removal is technically achievable.
CRS HIPEC combines two stages: cytoreductive surgery (CRS), which aims to remove visible tumour deposits where feasible, followed by hyperthermic intraperitoneal chemotherapy (HIPEC), in which heated chemotherapy is circulated within the abdominal cavity. The approach is complex and is not appropriate for every patient.
A useful part of treatment planning is determining the extent of peritoneal involvement before deciding whether surgery is suitable. Imaging, operative assessment and multidisciplinary discussion may all contribute to this decision. The potential benefits must be weighed against the complexity and recovery associated with major abdominal surgery.
Dr. Ninad Katdare is a Senior Consultant Surgical Oncologist with a clinical focus that includes gastrointestinal, gynecologic and peritoneal surface malignancies.
For patients exploring whether this approach may be relevant to their diagnosis, Dr Ninad Katdare Cancer Surgeon can be consulted in Dadar for individualised surgical assessment and treatment planning.
